Genomed Spólka Akcyjna (WSE:GEN)

Market Cap	34.35M
Revenue (ttm)	23.01M
Net Income (ttm)	1.11M
Shares Out	1.32M
EPS (ttm)	0.84
PE Ratio	30.99
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	50
Average Volume	76
Open	25.40
Previous Close	25.20
Day's Range	25.40 - 26.00
52-Week Range	25.20 - 33.40
Beta	0.04
RSI	39.64
Earnings Date	May 13, 2025

About Genomed Spólka Akcyjna

Genomed Spólka Akcyjna provides DNA analysis and congenital diseases diagnostic services in Poland. It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy. The company also offers the analysis of mutations responsible for congenital diseases in approximately 6,500 genes; and next-generation sequencing technology. In addition, it provides various types of DNA sequence analysis, including polymorphism analysis, and the sequencing of phage genetic material, ...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2007
• Employees: 48
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: GEN

Financial Performance

In 2024, Genomed Spólka Akcyjna's revenue was 23.01 million, an increase of 2.34% compared to the previous year's 22.48 million. Earnings were 1.11 million, an increase of 19.67%.